MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to lineage
-$63,533K
(-241.41%↓ Y/Y)
Net loss
-$63,367K
(-241.01%↓ Y/Y)
Net (income) loss
attributable to...
$166K
(514.81%↑ Y/Y)
Income tax benefit
-$5,280K
Loss before income
taxes
-$68,647K
(-269.43%↓ Y/Y)
Collaboration Revenues
$13,609K
Royalties License And
Other Revenues
$947K
Loss from operations
-$36,619K
(-70.50%↓ Y/Y)
Total other income
(expenses)
-$32,028K
(-1205.94%↓ Y/Y)
Total revenues
$14,556K
(53.24%↑ Y/Y)
Foreign currency
transaction gain (loss), net
$2,148K
(898.51%↑ Y/Y)
Interest income, net
$1,691K
(-1.40%↓ Y/Y)
Total operating
expenses
$51,175K
(65.20%↑ Y/Y)
Change in fair value of
warrant liability
$35,727K
(1778.90%↑ Y/Y)
Other income
(expense), net
-$132K
(80.30%↑ Y/Y)
Loss on marketable
equity securities, net
-$8K
(0.00%↑ Y/Y)
General and
administrative
$18,460K
(1.59%↑ Y/Y)
Research and development
$17,729K
(42.15%↑ Y/Y)
Loss on impairment of
intangible asset (note 6 and...
$14,840K
Cost of royalties
$146K
Back
Back
Income Statement
source: myfinsight.com
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)